1. CRR: Dismissal for cause  
   a. Taskforce has met for the first time  
   b. The goal is to protect the faculty while making sure the process is fair and the steps are clear to everyone

2. CRR: Consensual romantic relationship  
   a. Key edits include  
      i. Protecting undergraduates  
      ii. Addition of previous relationships as well as if things begin to emerge  
      iii. Ways to manage the relationship similar to managing conflict of interest  
      iv. Process for exceptions  
   b. Feedback  
      i. The age demographic may be different for undergraduates especially in urban campuses  
         1. Exceptions later in the policy  
         2. Some exceptions need to be stated earlier in the policy  
      ii. Proposed edit 3.2 after prohibited, except as described below in 4.3.1

3. CRR: Evaluation of the ability to work  
   a. Key edits include:  
      i. Grievances don’t stop the process  
      ii. Quicker process for immediate safety issues  
      iii. Committee that includes faculty members  
      iv. Removes provost requirements to bring in multiple other groups  
      v. Faculty coordinator role  
         1. Pulled out into Standard Operating procedures  
         2. They don’t vote  
         3. Changed it from a faculty role to an administrative staff/HR professional  
      vi. Added timelines  
   b. Feedback:  
      i. Just say business days instead of weeks and business days  
      ii. F1 evaluation – panel will review the verifiable evidence (F2a)

4. CRR: Faculty leave  
   a. Came up through IFC pre-COVID  
   b. Key edits include  
      i. Provides clarity of development leaves, length and payment  
      ii. Should be beneficial to the faculty member and the university – make the case before and demonstrate after  
      iii. Moved sabbatical to the top  
   c. This went to the Chancellors once COVID had hit and had some questions  
   d. Provosts still like the idea of sabbaticals but during COVID the timing to go to the Board seems off
5. Finance update (Ryan Rapp)
   a. Challenge is to understand long term ramifications
   b. State support is going to be fairly robust because of budget stabilization funds
   c. Thank you for all the work the faculty have done this semester
   d. Bigger question what is FY22 going to look like
   e. If remote only there would be a large impact to ancillary income especially at MU and S&T

6. President Choi
   a. FY21 is going to be okay because of the one-time support from stimulus report
   b. FY22 is going to be pretty severe
   c. Need to look into new ways of doing things, there will be a need for increased collaboration and communication
   d. eLearning
      i. How is this going? What are the plans moving forward? Where are we making progress?
      ii. Next Steps: eLearning to come to the February IFC meeting to present the progress

   e. Campus reports
      i. UMKC
         1. program evaluations reports
         2. reorganization taskforce
         3. promotion and tenure standards and guidelines to the departments to ensure they have similar processes in place
      ii. UMSL
         1. Academic prioritization
         2. Extra compensation
         3. Virtual graduation ceremony on the 19th each school launches at a different time
      iii. S&T
         1. Working on bylaw changes
         2. Accreditation Board for Engineering and Technology (ABET) visit 12/6-12/8 went very well and had a positive change since last visit
         3. Waiting on a decision for a provost
         4. Virtual graduation
         5. Email for retirees raises an issue of the value of emeritus/retired faculty
      iv. MU
         1. Curriculum should include Inclusion, Diversity and Equity (IDE) requirements
         2. New email policy suggested amendment
         3. Representation of ranked faculty on faculty council NTT and T/TT proposal mechanism to go back and ensure representation
         4. Student evaluations of teaching student comments in dossier
         5. Cancer research is growing rapidly, Dr. Carolyn Anderson
a. Contract worth $300 million with pharmaceutical firm to use in cancer treatments